Thrombin

Thrombin inhibitor 1 is a potent thrombin inhibitor with a Ki value of 0.66 nM and a 2xaPTT of 0.43 μM. This compound effectively inhibits thrombin activity, making it a valuable tool for studying blood coagulation and developing anticoagulant therapies. Its high specificity and efficacy render it suitable for various research applications in cardiovascular and hemostasis studies.

PPACK TFA is a potent and selective irreversible inhibitor of thrombin, demonstrating significant anticoagulant properties. It serves as an alternative to lithium heparin for blood gas and whole blood electrolyte analyses. Additionally, PPACK TFA inhibits plasminogen activator (rt-PA), interfering with its binding to plasma protease inhibitors, and mitigates plasmin-induced alterations in endothelial permeability and morphology in bovine aortic endothelial cell monolayers. This compound is valuable for investigations related to thrombosis and endothelial function.

PPACK dihydrochloride is a potent and selective irreversible inhibitor of thrombin. It serves as an alternative anticoagulant to lithium heparin for blood gas and electrolyte analyses in whole blood. Additionally, PPACK dihydrochloride inhibits plasminogen activator (rt-PA), preventing its binding to plasma protease inhibitors. This compound also reduces plasmin-induced endothelial permeability and morphological changes in bovine aortic endothelial cell monolayers, making it suitable for investigations in thrombosis-related research.

Ximelagatran is an anticoagulant that has been investigated extensively as a replacement for warfarin that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy.

Inogatran (H-314-27) is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of arterial and venous thrombotic diseases.

Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor.

RWJ-445167 (3DP-10017) is a dual inhibitor of thrombin and factor Xa with Ki of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity.

PPACK is a potent, selective and irreversible inhibitor of thrombin with a Ki value of 0.24 nM.

Odiparcil (SB-424323) is indirect thrombin inhibitor that exerts its anticoagulant effect through activation of antithrombin II (heparin cofactor II) .

Thrombin Inhibitor 2 is a small molecule direct thrombin inhibitor, extracted from US8541580B2. Thrombin Inhibitor 2 has antithrombotic activity.

Dabigatran ethyl ester hydrochloride is a potent inhibitor of ribosyldihydronicotinamide dehydrogenase (NQO2) with an IC50 value of 0.8 μM and a thrombin inhibitor.

OM-189 is a selective synthetic thrombin inhibitor.

Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin.

Bivalirudin is a synthetic 20 residue peptide which reversibly inhibits thrombin.

Dabigatran etexilate mesylate is the orally active prodrug of dabigatran. Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM.

Dabigatran ethyl ester, which is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity.

Hirudin is a potent thrombin inhibitor known for its anticoagulant properties. It exhibits significant anti-thrombotic activity and is implicated in therapeutic applications such as wound repair, anti-fibrosis, and anti-tumor responses. Additionally, Hirudin has been explored for its effects on diabetic complications and cerebral hemorrhage, making it a valuable reagent in various research contexts.

Isorhamnetin 3-O-galactoside is a flavonoid glycoside that acts as a thrombin inhibitor, isolated from Oenanthe javanica. It exhibits significant antithrombotic and profibrinolytic properties by inhibiting thrombin and factor Xa activity, thereby reducing the maximum rate of thrombin-catalyzed fibrin polymerization. Additionally, Isorhamnetin 3-O-galactoside suppresses TNF-α-induced PAI-1 secretion and decreases the PAI-1/tissue-type plasminogen activator (t-PA) ratio, making it instrumental in research on liver injury and thrombotic vascular diseases.

Argatroban monohydrate is a direct and selective inhibitor of thrombin. It plays a critical role in anticoagulation therapy, particularly for patients with heparin-induced thrombocytopenia. Argatroban is widely used in research to study coagulation pathways and evaluate potential therapeutic approaches for thrombotic disorders.